Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01245179 · ClinicalTrials.gov registry record · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
A Phase 1 study of Sickle Cell Disease, sponsored by Abdullah Kutlar.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01245179 is a Phase 1 study of Sickle Cell Disease that is actively recruiting participants, run by Abdullah Kutlar. The registered enrollment target is 18 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01245179, a Phase 1 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Abdullah Kutlar.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to find out about the safety and effects of a drug called panobinostat when given to adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor. HDAC inhibitors have been shown to significantly increase hemoglobin F induction, which is well documented to improve outcomes in sickle cell disease. HDAC inhibitors are also known to potently inhibit cell-specific inflammation, which is a primary contributor to the debilitating effects of sickle cell disease. Given the relevance of these mechanisms of action in SCD, panobinostat may prove to contribute significantly to the management of SCD patients, a population in critical need of further effective treatment options.
Conditions Studied
Interventions
- DRUG panobinostat
Study Locations (1)
Georgia
- Augusta University - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-11 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01245179
The ClinicalTrials.gov registry entry for NCT01245179 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (94% lower). The listed sponsor is Abdullah Kutlar, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which panobinostat is the first listed.
NCT01245179 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT01245179 about?
NCT01245179 is a clinical study titled "Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease". The goal of this clinical research study is to find out about the safety and effects of a drug called panobinostat when given to adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor. HDAC inhibitors have been shown to significantly increase hemoglobin F inducti...
What is the current status of trial NCT01245179?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-11. Estimated completion is 2027-01.
What conditions does trial NCT01245179 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT01245179?
The interventions under investigation include: panobinostat (DRUG).
Who is sponsoring clinical trial NCT01245179?
This trial is sponsored by Abdullah Kutlar, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01245179 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
RECRUITING · Phase 1
-
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
RECRUITING · Phase 1
-
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
RECRUITING · Phase 1
-
Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.